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Populärvetenskaplig
sammanfattning
Trots att antiretroviral behandling (ART) har visat sig väsentligt minska HIV och
progressionen av HIV-sjukdom, finns än idag ingen bot for HIV. Förekomsten av
en latent HIV-1-reservoar (LR) hos alla HIV-1-infekterade patienter tjänar som ett
stort hinder för fullständigt botande av en HIV-1-infektion. Hittills har det dock
inte funnits någon analysmetod som ger en noggrann mätning av reservoarstor-
leken. Syftet med den här avhandlingen är att ta itu med denna utmaning från
olika aspekter med flera nya teknologier varav både molekylära och mikrofluidik-
baserade verktyg används. För att hitta ett lämpligt verktyg att identifiera latent
HIV-1-reservoarer med optimerades och utvärderades (i artikel I och II) LIPS-,
RNAflow- och RNAscope-analys för indirekt och direkt LR-detektering. Resul-
taten indikerade att LIPS-metoden kan vara otillräcklig för LR-detektering, däre-
mot föreslås den för indirekt kvantifiering av reservoaren. Vidare presterade den op-
timerade RNAscopetekniken bättre än RNAflow för transkriptions- och translation-
skompetent LR-identifiering. RNAscope visade sig även vara oberoende av HIV-1-
subtypen och kan tillämpas på patientprover vid encellsnivå. Eftersom det för när-
varande inte finns några tillgängliga ytbiomarkörer för LR fastställdes i artikel III en
transkriptomik- och proteomikbaserad analysmetod för hög-kapacitetselektion av
potentiella biomarkörer, som sedan tillämpades i olika patientgrupper. Tolv mem-
branproteinkodande gener identifierades som nedreglerade i den patientgrupp som
var hypotiserad att ha en mindre latent reservoar. Dessa proteiner kan ha poten-
tial att användas som ytbiomarkörer för LR. CD4+ T-celler, monocyter/makrofager
och NK-celler antas vara den huvudsakliga källan för HIV-1-reservoarer i perifert
blod. I artikel IV utvecklades ett mikrofluidik-chip för att simultant isolera dessa
tre mononukleära leukocyter direkt från helblod. Mikrofluidik-metoden minskar
behovet av provvolym och är ett lovande verktyg för LR-studier. Sammanlagt,
även om ytterligare förbättringar och klinisk verifikation är nödvändig, har arbetet
i denna avhandling bidragit till framsteg i LR-karakterisering och kan komma att
underlätta den framtida utvecklingen av LR-targeting- och clearingsmetoder med
det ultimata målet att bota HIV-1-infektion.
Nyckelord HIV-1, latent HIV-1-reservoar, mikrofludik, molekylär detektion
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Abstract
The existence of latent HIV-1 reservoir (LR) in all HIV-1 infected patients
serves as a major obstacle to completely cure HIV-1 infection. However,
up to now there is still no available assay that provides an accurate mea-
surement of the reservoir size. This thesis aims to address this challenge
from di erent aspects with several novel technologies, using both molecular
and microfluidics-based tools. To find a proper tool to identify the latent
HIV-1 reservoir, in Paper I and II, LIPS assay, RNAflow, and RNAscope as-
say were optimized and evaluated for indirect and direct detection of latent
HIV-1 reservoir. The results indicated the LIPS method might not be su -
cient for latent HIV-1 reservoir detection, although it has been proposed to
quantify the latent HIV-1 reservoir indirectly. Furthermore, the optimized
RNAscope technique performed better than RNAflow for transcription and
translation competent latent HIV-1 reservoir identification. The RNAscope
was also found to be independent of the HIV-1 subtype and can be applied
to patient samples at single cell level. As there are currently no available
surface biomarkers for latent HIV-1 reservoir, in Paper III, transcriptomics
and proteomics-based analysis method for high-throughput selection of po-
tential biomarker were established and applied to di erent patient groups.
Twelve membrane protein-coding genes were identified as downregulated in
the patient group who were hypothesized to have lower latent reservoir. These
proteins might have the potential to be used as surface biomarkers for latent
HIV-1 reservoir. CD4+ T cells, monocyte/macrophages, and natural killer
cells are believed to be the primary source for HIV-1 reservoirs in peripheral
blood. In paper IV, a microfluidic chip was developed to simultaneously iso-
late these three mononuclear leukocyte cell types directly from whole blood.
The microfluidic method reduces the sample volume requirement and is a
promising tool for latent HIV-1 reservoir study. Together, though further im-
provement and clinical verification are necessary, the work in this thesis has
contributed to the advancement of latent HIV-1 reservoir characterization and
may facilitate future development of the latent HIV-1 reservoir targeting and
clearance methods with the ultimate goal – to cure HIV-1 infection.
Keywords HIV-1, Latent HIV-1 reservoir, HIV-1 characterization, Microflu-
dics, Molecular detection
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Chapter 1
Introduction
Viruses are obligatory parasitic particles, which replicate only in the host cells by
inserting its nucleic acid into the genome of the host cells. Many viruses, which
plague human are derived from animal population, periodically leap across the hu-
man population. In the case of Human Immunodeficiency Virus (HIV), this jump
seems to have occurred during mid 20th century and emerged as a devastating in-
fectious disease.
HIV infection weakens the immune system by targeting and destroying immune
cells, mainly the CD4+ T cells. As a result, the individual will become immuno
deficient and vulnerable to a wide range of immunological abnormalities, contribut-
ing to secondary infection and oncological diseases [1]. As the infection progresses
over several months to years, it will lead to Acquired immune deficiency syndrome
(AIDS).
The first report of AIDS was made in 1980, as a unique illness in homosexual
men [2]. In 1983, HIV-1 virus, a retrovirus was identified as the causative agent
for AIDS [3] [4], an illness that is still haunting several million people. According
to WHO 2017 report on HIV, around 36.9 million individuals live with HIV, as
shown in Figure1.1. Additionally, the new infection and HIV related death has
been significantly reduced by -14% and -34%, respectively, relative to 2010 [5].
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Figure 1.1: People living with HIV by WHO region. Source: UNAIDS/WHO
estimates
HIV is a retrovirus composed of Ribonucleic acid (RNA) genome; the virus has
an extraordinary capacity to copy RNA into Deoxyribonucleic acid (DNA) and in-
sert DNA into host cells, which will integrate into the host genome. Particularly,
viruses in the new host with no previous major adaptation are potentially danger-
ous. Consequently, integration of viral nucleic acid into the host genome remains
permanently. There are two types of HIV: HIV-1 and HIV-2 based on the di er-
ence in genetic characteristics and viral antigens [6]. HIV-1 was first isolated in
1983 by French scientists Francoise Barrre-Sinnoussi and others [3], whereas HIV-2
was isolated in 1986 from a western African patients with AIDS-like symptom [7].
HIV-1 accounts for most severe infection and more death than HIV-2, in this thesis
only HIV-1 was studied.
The discovery of Combination Antiretroviral therapy (cART) transformed HIV-1
infection from a lethal disease into a long-term chronic disease. cART is substan-
tially e ective at reducing HIV-1 replication, transmission and the progression of
HIV-1 disease by suppressing the viral replication [8]. cART can e ectively reduce
HIV-1 virus load to undetectable levels through disturbing the viral machinery
during infection. However, HIV-1 infection cannot be completely cleared by cART
suppression of viral replication and the virus reappears rapidly after treatment in-
terruption [9]. The rebounding of HIV-1 virus is mainly due to the latent infection
in some long-lived cells, especially in resting memory CD4+ T cells that harbor the
latent HIV-1 reservoirs, which is composed of inactive HIV-1 DNA integrated into
the genomes of these resting cells [7].
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Latent HIV-1 reservoirs (LRs) is a group of HIV-1 infected cells in resting state, in
which no viral particles are actively produced. It is one of the several mechanisms
used by HIV-1 for its persistence within the infected host, from which the infec-
tion could be reactivated under certain conditions [11]. Though cART can elim-
inate cell-free viruses, it is ine ective against proviruses integrated into the host
chromosome. Hence, the main obstacle for a HIV-cure is this persistence of the
latent reservoir as transcriptionally silent and integrated proviruses of which 90%
are non-functional [12]. Therefore, identifying the size and dynamics of the latent
HIV-1 reservoir during cART and how best to target it, is crucial for understand-
ing the barriers to curing HIV-1 infection and HIV-cure research. However, after a
decade’s research there are still no available surface biomarkers and proper estab-
lished method to identify, detect and isolate the latent HIV-1 reservoirs. Hence,
there is an urgent need for identification of new surface biomarkers and assays to
characterize the latent HIV-1 reservoirs in HIV-1 infected patients.
1.1 Objectives
In this thesis work, di erent molecular tools and microfluidic technology were em-
ployed to explore the potential latent HIV-1 reservoir biomarker, and developing
new methods to identify the latent HIV-1 reservoir.
1. Development of a detection method for latent HIV-1 reservoir
There is an urgent need for sensitive and specific assays to identify and detect
the latent HIV-1 reservoir containing inducible proviruses.
2. Development of a high-throughput approach to explore and identify
potential surface biomarkers for the latent HIV-1 reservoir.
Surface biomarkers are extremely important for in vitro latent HIV-1 reservoir
research; a high throughput approach is necessary to identify the potential
surface biomarkers to characterizes the latently infected cells. Furthermore,
surface biomarkers can also be used to selectively target and killing of latent
HIV-1 reservoir in vivo without the need for reactivation aiming towards HIV
cure.
3. Development of sample preparation devices for latent HIV-1 reser-
voir study.
CD4+ T cells, monocyte/macrophages and natural killer cells are believed to
be the main source for latent HIV-1 reservoir in peripheral blood. Microflu-
idics has the potential to e ciently isolate cell subsets from small volumes of
blood enabling latent HIV-1 reservoir research.
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Above-mentioned objectives were achieved and contributed through the following
studies:
1. Optimization and evaluation of three novel molecular assays for in-
direct and direct characterization of latent HIV-1 reservoir
An antibody-profiling assay was optimized and tested for profiling the an-
tibody against HIV-1 proteome in a well-characterized group of Swedish
patients, aiming to indirectly identify the size of latent HIV-1 reservoir by
the antibodies profiling signature (paper I). Furthermore, two novel signal-
amplification molecular assays were optimized and investigated for the ap-
plicability of direct identification of transcription and translation competent
latent HIV-1 reservoirs (Paper II).
2. Establishment of a transcriptomics and proteomics-based analy-
sis method for high-throughput selection of potential latent HIV-1
reservoir biomarker
A high-throughput transcriptomics and proteomics-based analysis method
was established and applied in a well-characterized group of Swedish HIV-
1 patients (paper III). Twelve di erent membrane protein coding gene were
identified and might be used as biomarkers of latent HIV-1 reservoir identifi-
cation.
3. Development of microfluidic-based cell subsets isolation device for
latent HIV-1 reservoir study
A microfluidics chip was developed for rapid isolation of three mononuclear
leukocytes separately as single cell-subset from a small volume of whole blood.
Furthermore, integration of microfluidics with the technologies developed in
Paper 1 and paper II might enable accurate identification and characterization
of HIV-1 reservoir at the single cell level.
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1.2 Thesis Structure
Figure 1.2: Overview of thesis structure

Chapter 2
Human Immunodeficiency virus-1
(HIV-1)
The HIV virus belongs to the family of Retroviridae [13], which contains non-
segmented RNA genome, essentially characterized by its mode of replication. The
virus replication depends on the hallmark enzyme: the reverse transcriptase that
has the ability to transcribe a single-stranded RNA into a double-stranded DNA
[14]. HIV can be vertically transmitted prenatally, perinatally and postnatally and
horizontal transmission and can occur as a cell free virus or as infected cells [15].
HIV has a remarkable genetic diversity. It is linked to numerous errors of incorpo-
ration of nucleotides by the reverse transcriptase, as the dynamic of viral replication
is intense (1 to 10 billions of viruses a day) [16] [17] [18]. There are two types of
HIV: HIV-1 and HIV-2 based on the di erence in genetic characteristics and viral
antigens [6]. HIV-1 was first isolated in 1983 by the French scientists Francoise
Barrre-Sinnoussi and others [3], whereas HIV-2 was isolated in 1986 from a western
African patients with AIDS-like symptom [7]. HIV-1 accounts for a more severe
infection and more HIV-related death cases than HIV-2. HIV-1 is composed of
four di erent groups: major (M), non-major (N), outlier (O) and group P based on
four independent cross-species transmissions from a simian immunodeficiency virus
(SIV) [13]. As the name suggests, the HIV-1 major group is responsible for the
major epidemic. This group is further phylogenetically classified into the subtypes
A, B, C, D, F, G, H, J, and K as shown in Figure 2.1.
2.1 HIV-1 Structure
Electron microscopy image of mature HIV-1 particle show that the virion is spher-
ical shape with a diameter of 80 to 120nm [19]. Infectious HIV-1 has an envelope
derived from cytoplasmic membrane from the host cells as the outermost layer that
carries glycoproteins (gp) spicules and structural Gag proteins, matric P17, P24
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Figure 2.1: Phylogenetic tree showing HIV-1 subgroups and distance between HIV-
2 subtypes. Reproduced from [13]
and P7 [20] as shows in Figure 2.2. Each spicule in the membrane is composed of
a transmembrane glycoprotein called gp41 and surface glycoprotein gp 120. The
envelope surrounds the cone shaped viral capsid, which consists of the capsid pro-
tein p24. The capsid core contains two identical single strands of RNA, which are
bound to two nucleocapsid proteins (p6/p7), as well as the viral enzymes, reverse
transcriptase, integrase, and viral protease. The reverse transcriptase is an RNA-
dependent DNA polymerase that is characteristic for retroviruses. The integrase
is necessary for the integration of proviral DNA into the host genome and the vi-
ral proteases are responsible for cleaving certain precursors polypeptides during
post-translational modifications [20].
The viral genome encodes for nine open reading frames and has three structural
genes: gag, pol and env [19] as depicted in Figure 2.3. Gag encodes the proteins for
the nucleocapsid (p7), the capsid (p24) and the matrix (p17), while pol encodes re-
verse transcriptase, viral proteases and integrase, The env encodes for the envelope
proteins (gp41 and gp120). The cleavage of gag and gag-pol polypeptide precur-
sors is carried out by the viral proteases, whereas cleavage of the env polypeptide
precursor by a cellular proteases. Additionally, the viral genome also includes ac-
cessory proteins Vif, Vpr, Nef and two regulatory genes Tat and Rev that plays
an essential role in the pathogenicity of the virus. Further the viral protein Vpu
required for virion assembly [20].
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Figure 2.2: Structure of a HIV-1 virion particle
Figure 2.3: Genomic organization of HIV-1( Ref Foley B T, Korber B T M,
Leitner T K, et al. "HIV Sequence Compendium 2018", Los Alamos National
Lab.(LANL), Los Alamos, NM (United States),2018.)
2.2 HIV-1 transmission and life cycle
Sexual transmission is considered to be one of the main routes for HIV-1 transmis-
sion, either as cell-free or cell-associated in semen or mucosal surfaces. There are
several other routes of transmission such as exposure to infectious blood or blood
components through blood transfusion, horizontally from infected mothers to in-
fants or by shared use of needles for drug injections [22]. Short viral generation
time and error prone HIV-1 reverse transcriptase increase the probability of genetic
changes resulting in extremely diverse viral populations within and between HIV-1
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infected individuals [22].
When the route of infection is through sexual transmission, it is unknown which
HIV-1 phenotype will be selected as a transmitter virus. However, the diversity of
HIV-1 is decreased when the infection occurs via blood. The recipient’s mucosal
membrane might act as a bottleneck for the entry of the virions or the infected
cells that enter the recipient’s genital organ [23]. It is, however, unknown how the
early events after the HIV transmission occur in humans. Studies from SIV about
mode of early transmission provides a role of partially activated CD4+ T cells of
the recipient’s genital mucosa [23] as shown in Figure 2.4.
HIV-1 might gain access to the recipient’s immune system with the assistance and
protection of the dendritic cells, langerhans cells and macrophages. The virus
crosses the epithelial layer [22] as shown in Figure 2.4 and binds to and enters
memory CD4+ T cells, its main target cell, where it initiates HIV replication.
Figure 2.4: Phases of infection following exposure to HIV-1 virus. Reproduced
from [23]
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2.3 HIV-1 replication
The replication cycle includeds di erent steps as shown in Figure 2.5.
i) Fixation and penetration of the virus: Entry of HIV-1 into CD4+ T cells starts
at the early phase of replication and requires a high a nity interaction between
one of the viral Env glycoprotein (gp120) to the CD4+ T cell surface proteins CD4
and chemokine receptors CCR5, CXCR6 or CXCR4 [24] [25]. Successful binding
will trigger the cascade of reactions shown in Figure2.5 that results in conformation
changes of several proteins. The virus to cell interactions leads to the the fusion
of virus and cell membranes, which will result in releasing of the viral content into
the cell [24].
ii) Decapsidation and eclipse: After decapsidation, based on the state and ma-
turity of the infected T cells, the reverse transcriptase transcribes the viral RNA
into double stranded DNA. Thereafter, newly synthesized viral DNA, called provi-
ral DNA, is transported into the nucleus as a pre-integration complex composed of
viral proteins and cellular protein. It is then integrated into the host genome by
viral integrase. In the late phase of replication, the neogenome is then transcribed
into pre-messenger RNA by the transcription machinery of the host cells. The pre-
messenger RNA matures and is spliced to become the messenger RNA, which then
migrates into the cytoplasm to be translated into polypeptide precursors [20] [26].
iii) Morphogenesis and release of new viral particles: The first viral polypeptide
precursors (gag, env) are cleaved by viral protease and become functional struc-
tural and enzymatic viral proteins, also env polypeptide precursors, the origin of
envelope viral proteins, are subsequently cleaved by cellular proteases. All these
elements are assembled before the new virus particles are released into the extra-
cellular medium by budding [27]. Di erent stages of replication cycles are under
the control of cellular and viral factors and in particular of HIV regulatory proteins
rev and tat.
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Figure 2.5: Life cycle of HIV-1 infection to CD4 T cell. Reproduced from [27]
2.4 Clinical and biological evolution of HIV-1 infection
In the absence of treatment, the HIV-1 infection progressively evolves. Three phases
can be distinguished during the process of progression: primary infection, clinical
latency or asymptomatic disease, and AIDS.
i) The primary infection phase: Primary infection is the period of invasion of the
virus into the recipient body. The viral replication is intense, the latent HIV-1
viral reservoir is constituted and an antiviral immune response appears gradually.
Clinically, the symptoms occur on average two to four weeks after exposure. All of
these symptoms define the primary infection syndrome.
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A persistent acute viral syndrome is, most often described as when a patient
presents with fever, myalgia and arthralgia and poly-lymphadenopathy, mainly cer-
vical, axillary and inguinal. Cutaneous manifestations (angina, pharyngitis, oral
or genital ulcers) and digestive symptoms (diarrhea) are frequently associated with
primary HIV-1 infection. More rarely neurological symptoms (meningo encephali-
tis, lymphocytic meningitis, mononeuropathy) occur [28].
Most of these symptoms gradually disappear; the lymphadenopathies can still per-
sist for weeks or even months. Biologically, primary infection syndrome is accompa-
nied by hematological abnormalities: thrombocytopenia, leukopenia, and neutrope-
nia. Hyperlymphocytosis, a mononucleosis syndrome or early lymphopenia can be
demonstrated. Hepatocytes anomalies,that mark asymptomatic and anicteric cy-
tolysis of the liver and can be revealed by a moderate elevation of transaminases
may also occur [28].
ii) Latency phase: The latency phase follows after phase of infection and is pau-
cisymptomatic or asymptomatic. This clinical latency masks the virological evo-
lution with persistence of infected lymphocytes, attenuated viral replication but
constant presence of viruses in the blood. Clinically, cutaneo-mucous signs (shin-
gles, warts, condyloma) can be observed [29].
iii) AIDS phase: The ultimate phase of HIV-1 infection is the acquisition of immun-
odeficiency syndrome. It is defined by all the opportunistic pathologies (infections
and tumors) related to HIV-1-induced immunosuppression. Recurrent oral or gen-
ital candidias), digestive (chronic diarrhea) or general symptoms (alteration of the
general state, abundant night sweats, feverishness etc) can sometimes appear or
reappear.
2.5 HIV-1 Diagnosis
Clinical signs present in approximately 50% of patients with primary HIV-1 infec-
tion as the consequences of activation of inflammation. They appear most often
within 10 to 15 days, and are similar to a pseudo syndrome that may persist for
up to 10 weeks after infection [30]. Nevertheless, clinical presentations depends
on individual variation and the intensity of symptoms is correlated with the HIV-
1 RNA burden [31]. The level of HIV-1 DNA in peripheral blood mononuclear
cells (PBMCs) is inversely correlated with the number of CD4+ T cells [32]. The
severity of the symptoms is correlated with the rapid evolution of the pathology.
Rapid HIV-1 infection is predicted by high level of HIV-1-RNA, HIV-1-DNA and
low primary CD4+ T cell counts [33]. Progressively, the intensity of the immune
reaction and the viral multiplication attenuate gradually and an immune-virological
equilibrium state is established to lead to a latent biological and clinical phase [34].
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The Enzyme-Linked Immuno Sorbent Assay (ELISA) is remain the reference method
for HIV-1 detection and are based on solid phase (beads or microplate wells) on
which antigens are adsorbed for HIV 1 and 2. The so-called 4th generation ELISA
tests allow the detection of antibodies and also P24 antigen enabling earlier detec-
tion of the infection (after 4 days on average). Rapid Orientation and Diagnostic
Tests (RODT) are recommended for screening for HIV-1 infection. There are dif-
ferent tests (such as immunochromatography, agglutination) that can be performed
on di erent biological fluids (plasma, whole blood, saliva). However, they are less
sensitive than the combined ELISA tests in the case of sampling during the sero-
conversion phase and their performance is lower on a salivary specimen [35].
In case of a positive ELISA test, a confirmation test will be performed. A sec-
ond blood test (ELISA) must then be performed. The combined tests may be
positive after 15 days infection by detection of p24 antigen and will require serolog-
ical testing by ELISA 15 days later. The confirmatory test is either an immunoblot
or a western blot (prior fractionation of viral proteins, denaturing electrophoresis
on polyacrylamide gel and transfer on a support type nylon, nitrocellulose and rev-
elations with labeled specific antibodies), which are more specific than the ELISA.
This makes it possible to detect antibodies directed against di erent constitutive
proteins of HIV-1 or HIV-2. A result is positive, if at least two bands are found
among the envelope glycoproteins (glycoproteins, gp41, gp120, gp160). The pres-
ence of these anti-envelope protein antibodies may or may not be associated with
antibodies directed against the gag and / or pol gene proteins. If the Western blot
is negative or indeterminate additional analyzes can be performed in case of suspi-
cion of primary infection [36].
Besides, p24 antigen is a viral replication marker that can be detected early by
a specific test, two to three weeks after the infection and can detect HIV-1 primary
infection in the case of western blot negative or indeterminate western blot result.
The quantification of viral RNA by polymerase chain reaction (PCR) in real time
can detect the presence of virus as early as seven to ten days after infection. The
kinetics of appearance of the antibodies, coupled with the quantification of HIV-1-
RNA and / or HIV-1-DNA (especially in the newborn) [36] as well as quantification
of the p24 antigen made it possible to define criteria of biological diagnosis of pri-
mary infection with classification.
Furthermore, acute infection can be defined by the presence of a negative or weakly
positive HIV-1 ELISA (3rd or 4th generation), with western-blot HIV-1 negative or
incomplete (Æ1 antibody) and a positive RNA-HIV and / or p24 positive antigen (I,
II, III stages). A recent infection can be defined by HIV1-positive ELISA test with
incomplete HIV-1 Western blot (Ø2 and <5 antibodies with presence of anti-p24
antibody, associated with the anti-gp160 or anti-gp120 antibody or anti-gp41) and
a positive RNA-HIV load (IV, V stages) [36]
Chapter 3
Latent HIV-1 Reservoir
At present, across the world, more than 35 million people are infected with HIV-1.
Thanks to the development of antiretroviral therapy (ART), the plasma viral loads
in infected individuals could be reduced to undetectable levels, and thus allowing
treated patients to have an average life expectancy [37]. Nevertheless, complete
cure of HIV-1 is still not achieve. If the ART is stopped, viremia will rebind within
a few weeks, even in long-term ART-treated patients.
The primary mechanisms that hinder HIV-1 eradication is the presence of and
residual replication of virus from a latent HIV-1 reservoir [38]. HIV-1 latency can
be defined as individual on treatment with ART for HIV-1 carrying subpopulation
of infected cells containing replication-competent HIV-1. Presently, latent HIV-1
reservoir has been detected in blood [39], lymph nodes [40], brain [41], and other
immune-privileged sites within di erent cell subsets [42], while the most well-studied
latent HIV-1 reservoir exists in resting memory CD4+ T cells [43] [44].
3.1 Molecular basis of latent HIV-1 reservoir
As mentioned earlier the HIV-1 provirus mainly depends on the host cellular ma-
chinery for production of virions. Therefore, the viral genome preferentially inte-
grates into the transcriptionally active region in the host genome [45]. However,
there are mechanisms down-regulating the expression of specific viral genes that
might intervene in the establishment and maintenance of viral latency. These types
of mechanisms can be divided in three groups [46] ,latency (trans acting e ect) reg-
ulating factors, viral gene deficiencies (cis-acting e ector) factors or a combination
of these factors as shown in Figure 3.1.
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Figure 3.1: Potential mechanisms of the latent HIV-1 reservoir at the molecular
level. Reproduced from [48]
The Trans acting e ect is an important mechanism for maintenance and establish-
ment of the latent HIV-1 reservoir, It is mainly regulated by the activation state of
the cell, availability and accessibility of transcription factors together with signal-
ing from environmental clues. Compaction of chromatin in nucleosomes opposite
to the viral promoter prevents the transcription factor access to the viral promoter
site. These changes are related to the state of methylation of polycomb protein
group [47], sumoylation, ubiquitinylation, phosphorylation and acetylation. Chro-
matin in the quiescent cells blocks the transcription in the non-acetylated form.
During activation of a cell, the chromatin opens up allowing easier accessibility for
transcription factors [48].
According to the state of cell activation there will be variation in the level of tran-
scription factors NF-kappa Beta and SP1, and these levels may be insu cient to
initiate the transcription at the promoter level [46]. In unactivated T-cells, these
are predominantly intra cytoplasmic.
The Cis acting e ects mainly depend on the integration site of the provirus, chro-
matin structure and the genome environment. Latency can be induced by mutation
in the viral genes including the tran-activating response element (tar) gene. More-
over, tat protein is necessary for the elongation phase, hence the transcription of
HIV-1 integrated genome might be prevented by the mutations in the tar gene [49].
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The Cis/Trans acting e ect plays an important role in integration and maintenance
of latency by intervening transcription depending on the polarity of virus integra-
tion. When the virus integrated in the same orientation as the cellular genes, the
weaker promoter will exhibit a decrease in activation. Another mechanism is the
overexpression of miRNA capable of preventing the translation of tat or rev protein
in quiescent host CD4 T cells [50]. Maintenance of viral latency results from com-
plex intracellular mechanisms that are regulating the expression and transcription
of the viral genome. Maintenance of the long-lived reservoir is one of the key factors
responsible for persistent residual replication and progressive destruction of CD4 T
cell. This is one of the major obstacles for eradicating the body of HIV-1 from the
body [51].
3.2 Dynamics of circulating lymphocyte subpopulations
After the early HIV-1 infection, latent HIV-1 reservoir might be establised in CD4+
T cells. Majority of theses cells die shortly after infection due to virus-mediated cy-
totoxicity or immune-mediated killing. Nevertheless, a small part of infected CD4+
T cells are capable of reversing to a resting memory state, and become silent in
producing viral particles. Since they have limited virus transcription and viral pro-
teins expressing, these cells are missed by the immune system or ART treatment,
and they can maintain or expand through cell proliferation of the infected cells that
still retains the proliferation ability. Therefore, these resting memory CD4+ T cells
are widely recognized as the main cellular latent HIV-1 reservoir nuturing latent
provirus [44].
The presence of subpopulations of memory lymphocytes represents a high level
of infection and makes important supplement to the latent HIV-1 reservoir. How-
ever infected naive or e ector T cells have low frequency of infection and contribute
less [52]. In addition, lower antigenic stimulation, long half-life and proliferation
capacity plays a key role in maintaining the reservoir for long term [53]. Low in-
fection of e ector T cells by R5 tropism virus might be due to weak expression of
these receptors on the T e ector cell surface [54].
In untreated chronic patients, there will be a reduction in e ector T cells and
inferior to uninfected patients, which may be explained by progressive fibrosis of
lymphoid tissues [55]. It has been reported that e ector T cell lymphocytes con-
tribute poorly to low-frequency reservoir of infection [56], and play a vital role in
maintaining homeostasis in congenital SIV-infected monkeys [57]. Higher levels
of infection was observed in central memory CD4+ T lymphocytes than in the
memory e ectors predominantly represent the reservoirs [58]. It has been shown
in chronic patients under treatment that the viral load was undetectable, but the
frequency of infection of memory, central, transitional and e ector subpopulation
cells were equivalent with a dominant contribution of e ector cells in homeostatic
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proliferation [59].
Moreover, in case of long term non-progressor patients central memory cells are
protected from infection and transitional subpopulation of cells contributes for most
to the reservoir. Also, the preservation of the number of central memory T cells
(TCMs), seems to be an ine ective element in the control of the viral infection.
3.3 Other cells involved in the latent HIV-1 reservoir
Existence of a latent HIV-1 reservoir in other cells than the quiescent CD4+ T cells
has been reported in treated patients with residual viral load. This is partly related
in virus production from other cells than CD4+ T cells [60].
Monocytes
Monocyte precursors of macrophages express the CD4 and CCR5 / CXCR4 recep-
tors of HIV-1 and can be infected with the HIV-1 Virus. They are highly resistant
to the cytopathic e ects of viruses and antiretrovirals do not easily enter these
cells [61]. It has been reported that the integrated HIV-DNA has been detected in
the monocyte cells of HIV-1 infected patients [62]. Their ability to produce virus
has also been demonstrated in patients with AIDS and 10% of macrophages can be
infected. In the chronic patient, they contribute less than 1% to peripheral blood
HIV-1 DNA [42] and the viral clones are phylogenetically distinct from those present
in CD4+ T cells [63]. Their short half-life of a few days before their macrophage
di erentiation and their significant turnover of macrophages suggest that these cells
represent a temporary reservoir of virus but are important because of their tissue
dissemination [64]. Macrophages can persist for years in compartments such as the
central nervous system and concentrate particularly in the mucosa of the gastroin-
testinal tract [64]. Macrophages are very migratory species, which gives them an
important role in maintaining the reservoir.
Dendritic cells
Dendritic cells that express low levels of elective receptor for HIV-1 CXCR4, CD4
and CCR5 can capture the virus on their cell surface through surface lectin pre-
sented on the cells. There are di erent types of dendritic cells, i.e. myeloid cells
that are present in ganglia, thymus, lympnodes and blood. Plasmacytoid dendritic
cells (PDCs) located in the mucousal membrane can be infected and produce virus.
Follicular dendritic cells, despite their short half-life have a high migratory prop-
erty and can spread the infection rapidly thus, playing a dynamic role for the latent
HIV-1 reservoir [65].
3.3. OTHER CELLS INVOLVED IN THE LATENT HIV-1 RESERVOIR 19
Natural Killer cells
Natural Killer (NK) cells have been poorly studied during HIV-1 infection [48].
A small fraction of NK cells express the CD4 receptor on their cell surface [67].
Longitudinal analysis of HIV-1 DNA in NK cells have indicated that NK cells can
become infected. However, another study found no evidence of NK cells infection
after 7 years of ART. The involvement of NK cells in latent HIV-1 reservoir persis-
tence remains to be elucidated [68].
B lymphocytes Some studies have shown evidence that B cells can become in-
fected in vitro if they express low levels of CD4 and CXCR4. Using a similar
mechanism as dendritic cells, B cells can capture the HIV-1 virus on their cell
surface and transfect CD4 T cell. The role of B lymphocytes and their role in
establishment of the HIV-1 reservoir remains unresolved [22].
In tissues
One of the major anatomical HIV-1 reservoirs is the lymphoid tissue, compris-
ing up to 98% of concentrated lymphocytes. CD4+ T cells are mainly found in
the secondary lymphoid organs. Basal ganglia play a vital role in the amplification
of virus considered as major reservoirs of HIV-1. Gut associated lymphoid tissue
(GALT) is another main reservoir composed of secondary lymphoid structures such
as Peyer’s patch and it contains macrophages, dendritic cells, plasma cells and 40
to 60% of the lymphocytes. Here, HIV-1 has access to a dense population of CD4+
T cells that are more susceptible to infection than circulating lymphocytes by the
expression of CCR5 or CXCR4 co-receptors of HIV-1. Intestinal CD4 cells are
therefore particular targets of HIV-1 being activated almost permanently because
of their exposure to a multitude of antigens. This allows for a potential spread of
the infection at the systemic level [69].
In humans, a 10-fold higher HIV-1 RNA burden has been reported in lymphoid
organs compared to peripheral blood. In treated chronic patients biopsies showed
3 times higher infection in duodenum and up to 10 times higher in the rectum than
in PMBCs [70] [49]. Moreover, the viral clone compartmentalization is di erent
from rectal colnes linked to viral replication in GALT [71] and plasma viral clones.
Therefore, GALT contributes to long-term viral production and remains an impor-
tant reservoir. The genital compartment is another source for persistence of the
virus. HIV-1 is found as free particle in the seminal fluid and embedded in the
infected leukocytes and can easily be detected in untreated patient. Even in the
female genital tract, HIV-1 is presented as free or integrated virus. It has been
shown that in 5 to 10% of patients the viral particle can persist in sperm after 6
month even with e ective ART, suggesting that the genital compartments probably
are a distinct reservoir site [72].
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A pathological finding from autopsies of the AIDS patient shows the presence of
virus in the central nervous system (CNS). In CNS several cell types can express the
CCR5 and CD4 receptors e.g. astrocytes, perivascular macrophages and activated
glial cells [73]. How macrophages and glial cells contributes to the latent HIV-1
reservoir is not well-studied [74]. Phylogenetic analyses revealed compartmental-
ization in macrophages and brain astrocytes of clones di erent from circulating
ones [75]. These clones were found in the meninges suggesting the production of
virons capable of migrating out of the brain brain [76]. Also, the poor penetration
of anti-retrovirals into cerebral parenchyma allows the viral protection and acts as
a reservoir.
3.4 Latent HIV-1 reservoir detection methods
Accurate quantification of the latent HIV-1 reservoir in HIV-1-infected individuals
is required for evaluating HIV-1 eradication strategies and for deciding on whether
and when ART interruption is legitimate. However, quantifying the size of the
latent HIV-1 reservoir is extremely challenging due to its rarity (only 10–100 in 106
of CD4+ T cells) and lacking detectable surface biomarkers [12], [77]. To date, many
molecules related to di erent stages of the HIV-1 replication cycle and the response
of the host’s immune system have been used as the biomarker for the latent HIV-1
reservoir detection, and the corresponding detection methods have been developed
to quantitate the latent HIV-1 reservoir in HIV-infected individuals after long-term
ART therapy (Figure 3.2).
3.5 Assays for Measuring the HIV-1 Latent reservoir
3.5.1 Viral load rebounding time
Typically, after cessation of ART, the HIV-1 virus will start to replicate again
from the latent HIV-1 reservoir and release to the circulatory system within just
a few weeks. Therefore, the time from ART interruption to viral load reach to
detection limit again was believed reflecting the size of latent HIV-1 reservoir [78].
The two most famous examples were the ‘Boston patients’ [79] and the ‘Missis-
sippi baby’ [80]. The ‘Boston patients’ were two HIV-1 infected patients on ART
treatment received stem cell transplants from a CCR5 wild-type donors. They had
an undetectable level of HIV-1 DNA after successful transplants, hence they were
believed to have a smaller latent HIV-1 reservoir than normal treated patients.
Consequently, these two patients kept the viral load under detection limit for up
to 8 months after stopping ART, while it usually was just few weeks for normal
patients [79]. In the same way, the ‘Mississippi baby,’ who was given 18 months of
ART treatment as early as 30 hours after birth from her HIV-1 positive mother,
enjoyed an even longer non-viremia time (27 months) without ART due to much
smaller HIV-1 latent reservoir size [80].
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Figure 3.2: Many molecular related to di erent stages of the HIV-1 replication
cycle and the response of the host’s immune system were used as the biomarkers
for latent HIV-1 reservoir detection and the corresponding detection method were
developed to quantitate the latent HIV-1 reservoir in HIV-infected individuals after
long-term ART therapy. Reproduced from [11]
However, there are not only method performance related problems but also ethical
issues need to be carefully considered before using this method, although treat-
ment interruption seems a simple way to estimate the size of latent HIV-1 reservoir.
The first limitation is the enormous variability in time to rebound. For example,
stochastic viremia rebound might happen if the latent HIV-1 reservoir is decreased
dramaticlly in size but not completely cleared, resulting in unpredictable rebound-
ing time after ART interruption [81]. Drug resistance is another drawback since it
can occur if the drug exists in the body at suboptimal drug concentrations for a
significant period [82]. As a consequence, compared to those on continuous ART,
the patients who interrupte ART treatment might have higher levels of morbidity,
opportunistic diseases, and malignancies [83]. Therefore, treatment interruption is
problematic in measuring latent HIV-1 reservoir size.
3.5.2 Viral outgrowth assay
The quantitative viral outgrowth assay (QVOA) (Figure 3.3) was the first assay
developed to identify and detect the size of the latent HIV-1 reservoir by measuring
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the frequency of cells that containing the replication-competent virus. To date, it
is still considered the gold standard for latent HIV-1 reservoir measurement [84].
QVOA typically starts with purifying the resting CD4+ T cells by density gradient
centrifugation and negative selection from HIV-1 infected individuals on ART. After
isolation, the resting CD4+ T cells are diluted in fivefold serial and stimulated with
phytohemagglutinin (PHA), followed by adding irradiated lymphoblasts from the
healthy donor to amplify virus replication. After 14 days incubation, the positive
wells are determined by detecting HIV-1 p24 antigen in the supernatant of each well
by ELISA. Finally, the frequency of cells containing the replication-competent virus
in initial sample is estimated based on maximum likelihood methods and expressed
as infectious unit per million (IUPM) [84].
Figure 3.3: The workflow of standard QVOA and the MOLT-4/CCR5 VOA. Re-
produced from [86]
.
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The QVOA has several advantages; the top one is the capacity to measure indi-
vidual latently infected cells that harbor the replication-competent virus. Another
advantage is the released viruses in positive wells can be isolated and character-
ized by sequencing and functional studies [38]. By utilizing QVOA, several studies
successfully revealed the frequency of latent HIV-1 reservoir in the blood of HIV-1
infected patients on ART were about one latently infected cell per million CD4+
T cells.
However, from the view of feasibility, QVOA is still far from being widely ap-
plied. The most notable, QVOA tends to underestimate the size of by 60-300 fold,
resulting from the ine ciency of a single round of PHA stimulation to reactivate
all intact provirus. The studies by Ho et al. [12]] showed that 98.5% of the viral
reservoir was not stimulated by one round activation, and 10–12% of non-induced
proviruses contain intact genomes and are potentially replication competent. Thus,
QVOA can only give a minimal estimation of the size of latent HIV-1 reservoir and
relies on the ability of latency-reversing agents (LRAs) to e ciently induce viral
expression from the latent HIV-1 reservoir [12]] [85]. Other reasons that hinder
QVOA translating from lab to clinic include intensive labor work and require a
large volumes of blood (120ml) and a longtime culture in a BSL3 lab (2 weeks),
which are not easy to get access.
Recently, several modifications of this assay have been reported. One of them
is using MOLT-4/CCR5 cells [86] (Figure3.3) or TZM-bl cell line [87] to replace
the donor cells for viral expansion. By this method, the volume of blood sam-
ple required is decreased as well as culture time, while no significant di erence or
higher sensitivity was observed on detected latent HIV-1 reservoir when compared
with QVOA. Furthermore, ELISA-based P24 protein detection after 14 days can
be replaced by quantitative PCR (qPCR) based HIV-1 RNA detection after seven
days, which can be used to reduce the total time [87].
Recently, another variant of QVOA using humanized mice (MVOA) was reported,
and it was also the first in vivo model, in which it was able to detect the latent
HIV-1 reservoir, enabling prediction of viral rebound time without harming the
patient status [88]. In this assay, up to 60 million isolated CD4+ T cells/PBMCs
from HIV-1 positive patients can be injected into one or several humanized mice,
followed by HIV-1 RNA monitoring with RT-PCR [88]. Pate et al. studies shows
that HIV-1 could be detected in mice after injecting cells isolated from participants
on ART, who have a viral loads under detection limit (<50 copies/ml). Hence,
MVOA is a relatively simple and sensitive tool for determining whether the latent
HIV-1 reservoir harbor the replication competent virus is present or not. However,
the MVOA assay cannot give the quantitative information of latent HIV-1 reser-
voir, and it has a high requirement for experiment condition (such as BSL3 animal
facility, animal handling and trained presonal), making it not sutiable for clinics.
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3.5.3 Monitoring of the HIV-1 DNA
In the HIV-1 replication cycle, there are three forms of cell-associated HIV-1 DNA
created that can be targeted individually or totally to estimate the size of latent
HIV-1 reservoir in HIV-1 infected patients, including integrated HIV-1 DNA, unin-
tegrated linear HIV-1 DNA and 2-Long terminal repeat (2-LTR) DNA circles [88].
PCR-based assays are commonly used to identify or quantify each HIV-1 DNA
form [89]. Most of the tests depend on the quantitative real-time PCR, while some
new methods have been introduced recently based on the targeted forms, such as
droplet digital PCR (ddPCR) for absolute quantification of HIV-1 total DNA [90]
and Alu-PCR for accurate measuring the integrated HIV-1 DNA [91].
So far, these approaches have been widely applied in various immune cell types
and tissue biopsies [92], which provide a quicker and simpler way to study viral
persistence, and have become a complementary method to the QVOA.
The most common target for PCR-based latent HIV-1 reservoir detection is the
total HIV-1 DNA in isolated immune cells or tissue [92]. The estimated frequency
of cells harboring HIV-1 DNA can be calculated by combining the total HIV-1
DNA copy number with the total number of cells present. In blood, one study
showed that the central memory CD4+T cells contributed most of the total pool
of HIV-1-infected cells, by using real-time PCR for the assessment of total HIV-1
DNA [39]. Within tissues, quantification of total HIV-1 DNA further showed resid-
ual HIV-1 infection in the gut and rectum of patients under ART [92]. Recently,
droplet digital PCR was introduced and compared with traditional quantitative
RT-PCR in monitoring of total HIV-1 DNA in patients on ART. The result of
this study showed that the signal to noise ratio was increased by droplet digital
PCR and the limit of detection was about three copies per million cells. Further-
more, ddPCR proved to be more robust in targeting HIV-1 sequence variations [90].
Though the total HIV-1 DNA-based method is simple and robust, it cannot dis-
criminate between integrative and non-integrative forms of HIV-1 DNA. Stevenson
et al. showed that in resting CD4+ T cells from viremic patients, the majority
of the HIV-1 DNA is linearly unintegrated, and are the end products of reverse
transcription before integration [93]. Furthermore, it was shown by several studies
that the linear unintegrated HIV-1 DNA is labile and replication-defective [94] [95].
Thus, cells with un-integrated HIV-1 DNA should not be included as latent reser-
voir.
Except the linear unintegrated HIV-1 DNA, 2-LTR and 1-LTR should also not
be considered as part of the LR. 2-LTR and 1-LTR normally generated when linear
unintegrated HIV-1 DNA fail to integrate within the cell, followed by nonhomol-
ogous or homologous end joining between the LTRs [97]. These two HIV-1 DNA
forms cannot integrate into host genome and produce infectious virus, hence they
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are normally not being considered as biomarkers of the LR, although 2-LTR circles
have been used as a biomarker for recent infection or ongoing replication because
of instability [98].
In order to solve the interference problem between linear unintegrated HIV-1 DNA
and 2-LTR HIV-1 DNA, Alu-PCR (Figure3.4) has been developed to distinguish
the integrated HIV-1 DNA from unintegrated genomes. In the first PCR step,
integrated HIV-1 genomes was selectively amplified by using one human genome
specific Alu elements primer along with another HIV-1-specific primer that bind to
the gag region. After this primary amplification, a second nested real-time PCR is
then applied by targeting the HIV-1 long terminal repeat (LTR). Finally, with the
help of the control which excludes the Alu primer, the detected signal can then be
demonstrated whether coming from integrated HIV-1 DNA or not [99].
Figure 3.4: Alu-PCR principle. Reproduce from bitesizebio.com
Recently, Eriksson et al. compared many LR detection methods and found there
was a strong correlation between the result of integrated HIV-1 DNA by using
Alu PCR and total HIV-1 DNA by adopting ddPCR in patients on suppressive
ART, showing that most of the HIV-1 DNA in the integrated form in the ART
patients [100]. This finding is further supported by others studies, showing that in
patients on suppressive ART, low levels of unintegrated HIV-1 DNAs are typically
found [101]. However, a recent full-length characterization of the integrated HIV-1
DNA revealed that more than 88% of such genomes were defective and unable to
produce replication competent virus [12]. Therefore, though Alu-PCR can provide
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more accurate latent HIV-1 reservoir size measurement by targeting integrated
HIV-1 DNA, but real size of the latent HIV-1 reservoir is overestimated much
higher compared to QVOA [100], resulting from quantifying both cells containing
replication competent and defective virus.
3.5.4 Testing of residual viremia
HIV-1 residual viremia can still be measured in the plasma of ART treated patients
using the single-copy assay (SCA). Although ART can e ectively suppress the viral
load to below the detection limit of clinical methods [102]. SCA is a highly sensitive
real-time RT-PCR based assay that uses primers targeted at a conserved region of
HIV-1 integrase and gag. It can detect as few as 1 copy of HIV-1 RNA in 1ml of
plasma [103].
Several previous studies analyzed the residual viremia by sequencing and confirmed
that the residual viremia mainly resulted from the virus production from an estab-
lished reservoirs [104]. In this sense, it might be able to be used as a measure of the
latent HIV-1 reservoir. However, the relationship between residual viremia and the
latent HIV-1 reservoir is complex and still unclear [38]. Furthermore, SCA cannot
distinguish the latent HIV-1 reservoir and replication-competent virus. Therefore,
the SCA method may not accurately reflect the dynamic of the latent HIV-1 reser-
voir in patients on ART therapy, though it is a powerful tool to measure the residual
viremia in plasma.
3.5.5 Measurement of the immune response
The host immune response to HIV-1 infection, especially the antibodies targeting
di erent HIV-1 antigens, can also be used as potential biomarkers to reflect the
latent HIV-1 reservoir size. A recent study reported that the anti-HIV-1 antibody
assay “luciferase immuno-precipitation systems (LIPS)” could exticate the HIV-1
infected individuals harboring di erent sizes of the latent HIV-1 reservoir. They
performed the quantitative humoral profiling of the presumably “cured” Berlin
patient, who has no or very limited latent HIV-1 reservoir, and the result revealed
that there were no antibodies against HIV-1 p24, matrix, nucleocapsid, integrase,
protease, and gp120, while low levels of antibodies against reverse transcriptase,
tat, and gp41 were found [105]. In contrast, the antibody levels persisted in most
well treated patients, while a small number untreated elite controllers (EC) had a
similar antibody pattern as the Berlin patient [105]. Furthermore, this finding were
supported by another study, in which it is shown that the anti-HIV-1 antibody level
decline to an undetectable level by immunoassay in primary HIV-1 infection (PHI)
treated patients [106]. Therefore, the levels of HIV-1 antigen-specific antibodies
may be a surrogate biomarker of the latent HIV-1 reservoir size. However, further
validation is required.
3.5. ASSAYS FOR MEASURING THE HIV-1 LATENT RESERVOIR 27
3.5.6 Detection of the cell-associated HIV-1 mRNA
In the HIV-1 life cycle, integrated HIV-1 DNA can transcripts to cell-associated
multiply spliced HIV-1 mRNA (msRNA) and the unspliced HIV-1 mRNA (usRNA)
in nucleus. The former one encoding the viral accessory proteins during early in-
fection, such as Tat, Rev and Nef, while the latter one encoding the viral structural
proteins at later stages of the infection, including the Gag–Pol precursor protein.
With the help of Rev all cell-associated HIV-1 mRNA are then exported into the
cytoplasm, where translation, assembly and release of the new viral particle from
the cells [107] (Figure3.5). Recently, in a comapartive study it has been shown that
virion release with intracellular mRNA measurements after stimulation, the result
revealed that only 1.5% of proviruses could be reactivated to produce HIV-1 virions
(replication-competent latent HIV-1 reservoir), while 6.8% and 8.2% of proviruses
from two di erent patients could be reactivated to produce cell-associated mRNA
(translation-competent LR) [85]. Hence, cell-associated viral mRNA can be consid-
ered as a more sensitive and accurate biomarker for latent HIV-1 reservoir detection
than others biomarkers.
Figure 3.5: The cell-associated mRNA in the life cycle of HIV-1, Reproduced
from [106]
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Recently, two novel cell-associated viral mRNA based detection methods were devel-
oped to identify the size of translation-competent latent HIV-1 reservoir: tat/rev-
induced limiting dilution assay (TILDA) [108] and the RNAflow [109]/RNAscope
[110]] single cell assay.
TILDA measures the CD4+ T cells that produce cell-associated tat/rev HIV-1
msRNA after maximal cell activation (Figure 3.6A). First, total CD4+ T cells are
isolated, followed by 12 h of stimulation with phorbol myristate acetate/Ionomycin,
follow by serially diluted in 22–24 replicates. After that, copy number of tat/rev
HIV-1 msRNA in each well will be detected by RT-PCR, and the latent HIV-
1 reservoir will be estimated by maximum likelihood method. As shown in this
study [108], the size of latent HIV-1 reservoir measured by TILDA in ART-treated
patients was estimated 24/million CD4+ T cells, 48-times larger than QVOA, and
lower than PCR based total viral DNA detection, supporting its ability to close the
gap between these two standard latent HIV-1 reservoir detection assays [108].
Figure 3.6: The workflow of TILDA (A) and RNAflow (B) for HIV-1 latent
HIV-1 reservoir detection. Reproduced from [109] [12]
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RNAflow/RNAscope is another novel CA HIV-1 mRNA detection method by com-
bining fluorescence in situ hybridization (FISH) technique and branched double-
stranded DNA signal amplification technology (Figure3.6b), and it normally also
coupled with concurrent antibody staining for phenotypic markers [109]. Briefly,
the target sequences of HIV-1 CA viral mRNAs are identified and bound by multiple
specific probes pairs, which make sure high specificity. This initial reorganization
signal is amplified and identified with fluorescent detection probes to drastically
increase the sensitivity, follow by result reading with FACS or microscope.
Consequently, CA HIV-1 mRNA and protein expression information of the latent
HIV-1 reservoir is acquired at a single-cell level with a high throughput, high speci-
ficity and sensitivity. Therefore, rare events and di erent gene expression pattren
can be identifed. This technology has been successfully used to detect the latent
HIV-1 reservoir in tissue samples [111] and isolated PBMCs [109] from infected
individuals.
These two novel technologies are highly attractive, not only because of the high
sensitivity, specificity and reproducibility, but also since they requires low input
numbers of CD4+ T cell and the results can be obtained in 2 days without any cell
culture or RNA extraction. Unlike others method, these two assays can be used
to study the latent HIV-1 reservoir at the single cell level and retain localization
information and provides more information about the heterogeneity of the latent
HIV-1 reservoir.
However, CA HIV-1 mRNA have similar drawback as QVOA. Since some defective
integrated HIV-1 DNA may still capable to transcribe mRNA and even able to
produce virions despite it is not infectious. Additionally, mRNA based assays men-
tioned above, only apply single round stimulation, thus they also unable to detect
intact noninduced proviruses within the LR. Besides, TILDA uses tat/rev region as
target, which is highly varible, thus introduces bias in viral detection. Nevertheless,
resulting overestimation of the LR by CA HIV mRNA-based assay is lower than
DNA based qPCR assay.Therefore, CA HIV-1 mRNA-based assay appears as an
appealing alternative to QVOA and PCR-based assays.
3.6 Latent HIV-1 reservoir and HIV-1 cure
There are two major concepts for HIV Cure, a sterilizing cure and a functional
cure. A sterilizing cure would be achieved by a complete elimination of the HIV
virus from the body. A functional cure on the other hand seeks to control the HIV
infection without anti-retroviral therapy. This would be achieved by strengthening
the immune system to naturally control remission.
Several strategies have been developed in hope of reducing and being able to con-
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trol the HIV reservoir. Strategies involve early initiation of ART, latency reversing
agent, immune therapy and gene therapy. These strategies can be divided into the
categories of expose, clear and protect. Expose means inducing the latent cells
to express HIV, thereby exposing to the immune system.. Some of the latency in-
hibitor agents are HDAC inhibitors such as Vorinostat, Panobinostat [112]. A single
dose of these agents is enough to activate the latency so that the immune system
can recognize HIV-1. The clearing strategy is improving clearance of infected cells.
Broadly neutralizing antibodies targeting HIV-1 and neutralizing the viruses, it
has been tested for prevention and cure. Not a single type of antibody have shown
enough e ciency in neutralizing HIV-1. However, it will require a combination of
di erent type of antibodies due to high variability of HIV-1. Interferon-alpha is
another agent that boosts the immune system [113]. Another way is to develop
therapeutic vaccine so that boost antibodies upon infection. However, combination
of expose and curing strategies are required to control HIV-1 [113]. Modifying, CD4
cells in another strategy making these cells impervious to HIV-1, one way could be
infusion of CD4 cells lacking CCR5 receptor or using CRISP/CAS gene therapy to
protect the cells. The recent finding that viral transcription does not halt at the
begin rather at downstream stage [114]. This result might provide better insight for
development of therapies to completely cure HIV infection. Therefore, increasing
the knowledge of how to measure and reduce the HIV-1 reservoir is needed to cure
HIV-1.
Several studies aim towards finding phenotypic biomarker for infected latent cells
have failed. Recent finding showed that CD32 generally expressed in myeloid rather
than lymphoid cells might be used as marker of infected cells enriched in HIV pa-
tient by the ART treatment [113]. However, this result has not been reproduced
in other studies. Therefore, a biomarker that could predict the clinical endpoint
would revolutionize HIV cure strategies..
3.7 Challenges
After the finding of the latent HIV-1 reservoir in resting CD4+ T cells and its
long-term lifecycle, many novel approaches to target, activate and eliminate the
latent HIV-1 reservoir have been developed, for instance “shock-and-kill” strategy
and di erent kinds of detection methods as discussed above. However, due to the
rarity and the lacking of available surface biomarkers of latent HIV-1 reservoir, the
identification of the real size of the latent HIV-1 reservoir is still very challenging.
As shown in the 3.7, the current gold standard method QVOA tend to under-
estimation the reservoir size, by which a treatment interruption might be misled
and result in virus rebound. On the other hand, overestimation of the reservoir size
by HIV-1 DNA based method might results in overdose of treatment and leading to
unnecessary side e ects. Therefore, in order to identify the true size of latent HIV-1
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reservoir, more research is required to identify surface biomarkers of latent HIV-1
reservoir and develop corresponding high-throughput, low cost and well-validated
detection assay.
Figure 3.7: Size of the latent HIV-1 reservoir from di erent methods. Recent stud-
ies indicate that most of the HIV proviruses detected by PCR based assays (yellow)
are defective. Replication-competent proviruses are detected by the viral outgrowth
assay (VOA, pink). However, single genome analysis of proviruses indicates that
the actual size of the reservoir of intact proviruses (blue) is larger that indicated
by the VOA by an average of 62 fold. These intact proviruses represent that true
barrier to curing HIV infection. Reproduced from [12]

Chapter 4
Microfluidics and HIV-1
Microfluidics is a term used to describe the studies of transport of fluids in chan-
nels of transverse dimensions ranging from a few micrometers to a few hundred
micrometers. At this scale, the characteristic of fluid flow is defined by dimension-
less Reynolds number as given in the (Equation 4.1).
Re = ﬂUDh
÷
(4.1)
where U is the fluid drag velocity, Dh = characteristic length depends on channel
geometry, ÷= dynamic viscosity, ﬂ=density.
Typically, the Reynolds number (which describes the ratio of inertial forces/ viscous
force) is often very low in microfluidics, often less than 1. In a pressure driven flow
in microchannels the flow is typical laminar in microfluidics, such that the layers
of fluid flow in parallel and has the highest velocity at the middle of the straight
channel forming a parabolic velocity profile [115], as shown in figure 4.1.
Due to the laminar flow behavior, precise control of individual cells in blood can
be e ectively accomplished at the microscale level. Hence, microfluidic lab-on-a-
chip devices have the potential to enable the miniaturization of complex reaction
processes into small, self-contained packages. The most attractive features of mi-
croscale approaches for blood analysis include the requirement for only microliter
blood volumes obtainable without venipuncture, and simple operation by minimally
trained personnel.
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Figure 4.1: Laminar flow within a microfluidic channel has a parabolic flow profile.
There are a number of HIV screening tests for adults, such as enzyme-linked im-
munosorbent assays (ELISAs) and simple/rapid assays often in the form of lateral
flow strips or cassettes. However, for staging and ongoing monitoring of HIV, the
“gold standard” tests today are direct viral load quantification and CD4+ T cells
counting.
In the interest of improving the accessibility and a ordability of high-quality ART,
there is a growing demand for simple, a ordable, reliable and quality-assured point-
of-care (POC) diagnostics for use in resource-limited settings. For resource-limited
settings, it is often suggested that diagnostic tests for use at the point of patient
care should meet the ASSURED criteria for the ideal rapid test. The ASSURED
criteria [116], coined by WHO, are as follows: A ordable by those at risk of in-
fection, Sensitive (few false-negatives), Specific (few false-positives), User-friendly
(simple to perform and requiring minimal training), Rapid (to enable treatment
at first visit) and Robust (does not require refrigerated storage), Equipment-free
(minimum equipment) and Delivered to those who need it.
With the capacity of precisely control and manipulation of small volume of fluids,
microfluidics technology o ers new opportunities to develop ASUURED-fulfilled
point-of-care devices for HIV-1 diagnosis, such as CD4+ T cells counting [117–122]
viral particle isolation [122,123,130,135,138], viral load quantification [90,141–143]
and HIV-1 latent reservoir detection [144].
Since CD4+ T cells are the primary targets of HIV-1, the CD4+ T cells number be-
comes an important diagnostic indicator for HIV-1 diseases progress and treatment
management. The CD4+ T cells count for a health person is normally between 500
and 1500 in per milliliter whole blood, while normally below 200 cells/ml blood for
AIDS patients without treatment and over 500 cells/ml for well-controlled HIV-1
infected patients [119]. Recently, several microfluidic-based devices for immune-
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capturing and enumeration of CD4+ from HIV-1 patient blood sample were re-
ported [117–122].For instance, a inexpensive, rapid and portable lab-on-DVD mi-
crofluidic platform together with a modified commercial DVD reader was devel-
oped to perform fully automatic CD4 cell count [118]. Besides, di erential shear
stress [120] and counting algorithms [117] were also developed for capturing and
counting of CD4+ T cells on the microfluidics device, make it more accurate and
e cient than manual counting. Furthermore, using a size-coded mixture of multi-
ple a nity-capture microbeads and an inertial microfluidic particle sorter device,
low abundance antibodies specific to di erent HIV antigens and rare HIV-specific
cells from blood were isolated from HIV-1 infected patients [130].
In addition to CD4+ T cells counting, viral load quantification is another impor-
tant measure for HIV-1 disease progress. Today there are many devices available
for molecular based HIV-1 diagnosis, such as Alere q system, Cobas Liat, Eoscape
HIV-1 rapid RNA assay system and GeneXpert HIV-1 viral load test and ExaVir
load viral RNA assay. However, these diagnostic methods require expensive instru-
ment and highly trained personnel. Often each of these methods follows the same
elaborate three-step process. First, HIV particles in plasma are separated from
other components of blood and lysed to release viral RNA, which is then purified.
Second, the purified RNA is amplified by several orders of magnitude to allow for
fluorescence-based detection. Third, the amplified nucleic acid is detected, either in
“real-time” simultaneous with amplification, or following amplification, using fluo-
rescence detection methods. Recently, several microfluidics device were reported to
be able to isolate viral particles with high e ciency [138] or amplify HIV-1 nucleic
acid with isothermal amplification methods such as LAMP [142]. Furthermore, re-
cently, the entire process including cell lysis, extraction of DNA, polymerase chain
reaction (PCR), and optical detection have been successfully integrated on one
microfluidic system, in which equipped with a sample pretreatment device and a
nucleic acid amplification device for the rapid and automated diagnosis of HIV-1
viral load [143].
Droplet microfluidic is a new technique, which uses two-phase system, generat-
ing aqueous droplets in an immiscible oil medium [145]. Each droplets act as a
single reaction container, thus enabling high throughput analysis of single cells or
molecules [146] Recent studies showed that droplet microfluidics technology could
be used to sort millions of HIV-1 particles with >99% e ciency [138], and to
perform digital PCR for absolute quantification of HIV nucleic [90]. Moreover, a
microfludic single-cell-in-droplet (scd) PCR assay were developed for direct mea-
surement of latent HIV reservoir after external activation of infected CD4 cells from
HIV patients, and suggested that HIV latency reversal is high heterogeneous [144].

Chapter 5
Present Investigation
This thesis is based on the structure as shown in the Figure1.2 and this chapter
describes the results presented in paper 1-4.
Firstly, I discuss the applicability of three novel molecular assays for latent HIV-1
reservoir characterization. In Paper I, an antibody profiling method was optimized
and used to verify the hypothesis that the anti-HIV-1 proteome antibodies signa-
ture in HIV-1 infected patients could indirectly reflect the size of HIV-1 reservoir.
In paper II, we optimized and investigated the capacity of two branched DNA
amplification (bDNA)-based methods, that target to cellular HIV-1 mRNA in the
latent HIV-1 reservoir after activation, to directly detect inducible transcription
and translation-competent latent HIV-1 reservoir.
Secondly, in paper III, I present a transcriptomics and proteomics-based high-
throughput approaches, which were established and utilized to study the immune-
control mechanisms of HIV-1 infected elite controllers, as well as identifying poten-
tial biomarker for latent HIV-1 reservoir.
Finally, in paper IV, I presents the development of an integrated microfluidics chip
to isolate three primary mononuclear leukocyte cell subsets that can harbor the
latent HIV-1 reservoir, namely monocyte cells, CD4+ T-lymphocytes, and natural
killer (NK) cells, from a small volume of whole blood.
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5.1 Paper I and II
5.1.1 Optimization and evaluation of three novel molecular
assays for indirect and direct characterization of latent
HIV-1 reservoir
After more than 30 years of study, identifying the size and dynamics of the latent
HIV-1 reservoir during cART and how to target it, is still an unsolved problem and
have become an obstacle for the design of strategies to eliminate the latent HIV-1
reservoir and cure HIV-1 infection. Therefore, there is an urgent need for an assay
that can identify the size of the latent HIV-1 reservoir and distinguish the inducible
latent HIV-1 reservoir from defective proviruses with high precision.
Several previous studies have reported that the anti-HIV-1 antibodies profiling can
reflect the size of the latent HIV-1 reservoir in HIV-1 infected individuals [139] [105].
In paper I, we adapted and optimized the antibody-profiling assay “luciferase im-
munoprecipitation systems (LIPS)”. Based on this method, we screened the anti-
body levels against the HIV-1 proteome in a well-characterized group of Swedish
patients and verified the hypothesis that the anti-HIV-1 antibody level in HIV-1
infected patients can indirectly reflect the size of the HIV-1 reservoir.
Figure 5.1: The result of antibodies profiling against sex HIV-1 proteome in a
well-characterized group of Swedish patients. Lines, boxes and whiskers represent
median, interquartile ranges, and range respectively.
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The antibodies against HIV-1 RT, Tat, p24, gp41, protease and integrase were
profiled using optimized LIPS assay in in a well-characterized group of Swedish
patients, included 19 elite controllers (ECs), 38 viremic progressors and 19 patients
with fully suppressive long-term antiretroviral therapy (ART)(mean 17 years).
As a result, the long-term suppressive ART patients contain lower antibody levels
to gp41, reverse transcriptase, p24 and protease, compared to the viremic patients
and the ECs. Nevertheless, between viremic patients and the ECs, we did not
observe a statistically significant di erence. For the antibodies against HIV-1 inte-
grase and tat, compared to viremic patients, they were found to have a significantly
lower level in the ECs and the patients with long-term ART. (Mann Whitney U
test; p<0.05 for all analysis) (Figure 5.1)
The PCA and hierarchical clustering analysis results (Figure5.2) further indicated
that the antibodies against HIV-1 replication enzymes (reverse transcriptase, pro-
tease and integrase)might perform better than the HIV-1 structural proteins (e.g
Gag or Env proteins) for disease state classification as well as identification of size
of the latent HIV-1 reservoir.
Figure 5.2: The PCA and hierarchical clustering analysis results based on the four
HIV-1 antigens and the total antibody response.
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In summary, our data indicated that the anti-HIV-1 proteome antibodies level was
low in the HIV-1 patient who received long-term cART treatment, which was ex-
pected and can be explained by the limited latent HIV-1 reservoir and low antigen
expression. However, beyond our expectation, this method failed to distinguish
HIV-1 elite controllers (EC) expected to have a low level of HIV latent reservoir
from viremic patients expected to have a high level of HIV latent reservoir. Though
these ECs in our study were selected with strict criteria and followed for more than
15 years and were expected have smallest latent HIV-1 reservoir as well as lowest
anti-HIV-1 antibodies level. Hence, we concluded that there is certainly room for
this method to improve, especially in sensitivity and specificity.
The primary aim of Paper II was to optimize and evaluate two novel branched
DNA amplification (bDNA)-based molecular assays, namely PrimeFlow™ RNA
Assay (RNAflow) and RNAscope® ISH (RNAscope), for identification of the tran-
scription and translation competent latent HIV-1 reservoir through detection of
cellular HIV-1 specific mRNA after latency reversal agent activation.
The workflow is shown in Figure5.3. Based on three latent HIV-1 reservoir cell
models (J-Lat cell model, clones 6.3, 9.3 and 10.6), four latency reversal agents were
optimized with respect to the combination and dose to achieve maxium latent HIV-
1 reservoir activation. Subsequently, under the optimized condition, the RNAflow
and RNAscope assays were evaluated for sensitivity, specificity, and lower detection
limit for the identification of the translation-competent HIV-1 reservoir. The HIV-1
subtype specificity of the RNAscope assay was also verified using patient-derived
subtype A1, B, C and CRF01 AE recombinant plasmids following transfection
in 293T cells. Finally, as a proof-of-concept, optimized RNAscope was applied
in patient derived peripheral blood mononuclear cells (PBMCs) to indentify the
translation-competent HIV-1 reservoir after activation.
Figure 5.3: The schematic workflow for RNAflow and RNAscope.
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Figure 5.4: Gating strategy (a) and determination of the lower detection limit of
RNAflow linear equation (y = meanblank + 3SDblank).
As shown in Figure 5.4 and Figure 5.5, RNAflow has 575 HIV-1 infected cells/million
as the lower detection limit. In contrast, the lower detection limit for optimized
RNAscope was 45 cells/million, a 10-fold lower than the former and with higher
specificity and less cell loss. Furthermore, we also showed that the RNAscope
method can also detect several other patient-derived HIV-1 subtypes (HIV-1A1,
HIV-1B, HIV-1C, 01 AE), though the probes for RNAscope were developed based
on HIV-1B. Finally, we also showed that the translation-competent HIV-1 reservoir
could be detected by this optimized RNAscope method in patient derived PBMCs
after activation (Figure5.6), and allow single cell characterization of HIV-1 RNA
and protein simultaneously.
In summary, this study compared the performance of two novel and sensitive molec-
ular assays in translation-competent HIV-1 reservoir detection. The result indicated
that the optimized RNAscope techniques has a higher sensitivity and less cell loss
than the RNAflow, and is independent on the HIV-1 subtype. We also showed that
RNAscope could directly identify and quantify the individual translation-competent
latent HIV-1 reservoir, which is expressing HIV-1 mRNA after activation. Hence,
this optimized RNAscope method can be a valuable means for characterization
of the translation-competent latent HIV-1 reservoir at single-cell resolution, not
only for quantification but also for single-cell transcriptomics and proteomics study,
when combined with a proper single-cell isolation method.
42 CHAPTER 5. PRESENT INVESTIGATION
Figure 5.5: Determination of the specificity (a) and the lower detection limit (b)
of RNAscope.
Figure 5.6: Counting of activated HIV-1 latent cells in patients derived PBMC
by RNAscope, error bars represent the standard deviation among three independent
replicates.
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5.2 Paper III
5.2.1 Establishment of a transcriptomics and proteomics-based
analysis method for high-throughput selection of potential
latent HIV-1 reservoir surface biomarkers
To date, there is still no available surface biomarkers for the latent HIV-1 reser-
voir. One main reason is because of the lack of su cient identification and isolation
methods for latent HIV-1 reservoir, which we tried to adress in paper II. Another
reason is the low-throughput of traditional FACS-based surface biomarker selection
methods. Thanks to the development of the next generation sequencing, searching
and exploring the potential surface biomarkers at gene and protein level with high-
throughput may o er more hints than tranditional methods. Hence, in paper III,
we tried to establish a transcriptomics and proteomics-based analysis method for
high-throughput selection of potential latent HIV-1 reservoir surface biomarker at
gene and protein level.
As a model, we established a research pipeline that combining transcriptomics with
targeted proteomics analysis based on the isolated PBMCs from a well-defined
Swedish HIV-1 infected patients cohort with up to 20 years of clinical follow-up
data (Fig 5.7), with the aim to apply this method after we achieve isolation the
latent HIV-1 reservoir from patient blood sample. In this study, 19 untreated elite
controllers (ECs, the group of individual who control viral replication spontaneously
and hypotheised to be have low latent reservoir), 32 treatment naïve patients with
viremia (VP, who were hypotheised to be have high latent reservoir) and 23 HIV-
1-negative healthy controls (HC) were assayed with this approach.
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Figure 5.7: The patient cohort, study designing and analysis plan of this tran-
scriptomics and proteomics study.
As shown in Figure 5.8, out of 159 up-regulated protein coding genes, 12 membrane
protein-code genes (CCR5, MELK, CAV1, PTPN3, TNFRSF17, CXCR6, SSPN,
GPRC5D, TSHR, SLC16A14, SIGLEC1 and ABCG2) were found up-regulated in
treatment naïve patients with viremia who were hypothesized to have high latent
reservoir compare to elite controllers, who were hypothesized to have low latent
reservoir, and might have the potential to serve as biomarkers for LR. Further
study is till on going to validate this finding.
Figure 5.8: The fold change value of twelve membrane-protein coding genes,VP
against EC
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5.3 Paper IV
5.3.1 Development of microfluidics-based cell subsets isolation
device for latent HIV-1 reservoir study
CD4+ T cells, monocyte/macrophages and natural killer cells are believed to be
the main source for HIV-1 reservoirs in peripheral blood. However, current HIV
latency studies are mainly based on PBMCs or only CD4+ T cells, due to the
lack of appropriate cell subset isolation method. These cells were normally iso-
lated by conventional cell isolation techniques, such as fluorescence-activated cell
sorter (FACS), magnetic activated cell sorting (MACS) and centrifugation systems.
However, these techniques o er several limitations, such as the requirement for
large sample volumes, high reagent consumption, cross contamination of samples
and expensive equipment cost. Hence, in paper IV, we developed an integrated
microfluidics chip to isolate three primary mononuclear leukocyte cell subsets that
can harbor HIV latency, namely monocyte cells, CD4+ T-lymphocytes, and natu-
ral killer (NK) cells, from a small volume of whole blood in short time.
In order to achieve high capture e ciency as well as purity, the shear stress force and
immunoa nity were combined and optimized before the final design of the mononu-
clear leukocyte-capturing chip. The three cell lines mixture (in which has the same
proportion as in blood) was pumped into antibody-immobilized Hele–Shaw chips,
which allows the analysing of the cell adhesion over a range of shear stresses in a sin-
gle experiment (Fig 5.9). As shown in Fig 5.10, 1.7 dyn/cm2, 1.1 dyn/cm2 and 0.9
dyn/cm2 were determined as the optimal shear stresses for CD4+ T cells, NK cells
and monocyte cells capture in microfluidic chip. After optimization of the shear
stress for cell capture using Hele-shaw chip, the capturing device was designed and
fabricated with standard lithography technology. The surface of the three cham-
bers in this integrated microfluidic device is coated with anti-CD4, anti-CD56 and
anti-CD14 antibodies respectively, to specifically capture CD4+ lymphocytes, nat-
ural killer cells and monocytes. Eventually, this chip was tested with 200 µl of cell
mixture suspension and whole blood sample.
When tested the capturing in cell line mixture suspension sample, the results show
that the average number of CD4+T cells captured in the CD4 capture chambers of
the chip was (131490) with 85% of purity. While, the average number of monocyte
captured cells in monocyte chambers was (44082) and the capture purity was 64%,
the mean capture of NK cells in NK chambers was (49749) with 67% purity as
shown in (Figure.5.11 A and B). For whole blood sample, the highest cell subset
capture was in lymphocytes (106382) with 76% purity. The average number of
monocyte capture was (4696) and the capture purity was 41%, while, the capture
of other leukocytes was higher in monocyte chambers than other chip chambers.
NK cells capture average from whole blood was (13115) and the capture purity was
47% as seen in (Figure.5.11 C and D).
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In summary, we demonstrated a simple, quick and integrated microfluidic device
based on immunoa nity capture of three subpopulations of mononuclear leukocytes
(lymphocyte, monocyte and NK cells), from small volumes of whole blood, within
20min. The device operated under controlled shear stress. To our knowledge, this
is the first design that can isolate the three mononuclear cell populations, which are
involved in the HIV latency mechanism in a single step. In future, this microfluidic
chip can be combined with the technology we developed in the paper I and III, to
characterize the HIV-1 latent reservoir in an isolated single cell subset.
Figure 5.9: The Microfluidic chips design. (A) Geometry of the Hele–Shaw device.
The Hele–Shaw device o ers a linear variation of shear stress along its central line.
It was used in this study to determine the optimal shear stress for di erent cell
capture. (B) Cell capturing device, the chamber bottom surface was modified and
immobilized with neutravidin and specific biotinylated antibody to capture target cells
from whole blood
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Figure 5.10: The shear stress optimization result based on Hele–Shaw chip ex-
periment. The representative images of captured and stained cells (CD4: green,
Monocyte: yellow, NK cell: Red) in the Hele–Shaw chamber at di erent locations
corresponding to di erent shear stresses. (A, B, C) The relationship between shear
stress and captured cell density of CD14+cells (monocytes), CD4+ T cells and
CD56+ cells (NK cells) in the Hele–Shaw chip. Error bars represent the standard
deviation among three independent replicates
Figure 5.11: Capture of CD4+T cells, monocytes and NK cell lines in the cap-
turing device from cell line suspension and whole blood. Error bars represent the
standard deviation among three independent replicates

Chapter 6
Conclusion and outlook
Due to the rarity and lack of detectable surface biomarkers, to develop robust as-
says that can characterize the latent HIV-1 reservoir is still a major challenge in
HIV-cure research. The papers presented in this thesis aims to address this chal-
lenge from di erent aspects using di erent novel technologies.
In order to find a proper tool to identify the latent HIV-1 reservoir, three molec-
ular assays were optimized and evaluated for indirect and direct characterization
of latent HIV-1 reservoir. First, in Paper I, LIPS assay was optimized and tested
to profiling the antibody against HIV-1 proteome in a well-characterized group of
Swedish patients, aiming to indirectly identify the size of latent HIV-1 reservoir by
the antibodies profiling signature. However, though LIPS has been proposed for
the indirect quantification of latent HIV-1 reservoir, our study showed it might not
be a su cient method for latent HIV-1 reservoir characterization, as it failed to dis-
tinguish the HIV-1 positive elite controller (EC) who possesses low level of latent
reservoir from the viremic patients who has high level of latent HIV-1 reservoir.
Besides, from Paper I, we also can conclude that EC may not be an ideal model
for HIV-1 cure due to its heterogeneity. Rather long term successfully treated ART
group can be a good model of HIV-1 cure.
Secondly, in Paper II, RNAflow and RNAscope assay were further investigated
for identification of transcription and translation competent latent HIV-1 reservoir.
Our result indicated that our optimized RNAscope technique performed better than
RNAflow for transcription and translation competent latent HIV-1 reservoir iden-
tification, especially in a small volume of samples due to the less cell loss. The
RNAscope was also found to be independent of the patient-derived HIV-1 subtype.
Besides, the optimized RNAscope also have the potential to combine with laser cut-
ting to isolate single latent HIV-1 reservoir for downstream analysis. However, since
the lower detection limit of RNAscope is still higher than the number of mathemat-
ically predicted replication-competent HIV-1 reservoir (10-100 copies/106 PBMC),
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the RNAscope method still need further improvement.
As there were no available surface markers for latent HIV-1 reservoir cells, in paper
III, a transcriptomics and proteomics-based analysis method for high-throughput
selection of potential biomarkers were established and applied in di erent patient
groups. 12 membrane protein-coding genes were identified as upregulated in the
patient group who were hypothesized to be have low latent reservoir, and might
have the potential to serve as surface biomarkers for the latent HIV-1 reservoir.
Nevertheless, given the small number of samples, it was di cult to validate. A
larger sample size will be needed to prove it, a work is presently ongoing. Besides,
it could also be beneficial to apply this method on individual cell populations, by
combine with our cell subset isolation microfluidic chip in paper IV, as the expres-
sion of those markers di ers between the cell populations.
CD4+ T cells, monocytes/macrophages and natural killer cells are believed to be
the main source for HIV-1 reservoirs in peripheral blood. In paper IV, a microflu-
idics chip was developed to isolate these three mononuclear leukocytes as single
cell-subset from whole blood samples in short time. More e ort is needed to im-
prove the capture purity and yield from blood samples. In future, this microfluidic
chip can be combined with the technology we developed in the paper II and III, to
characterize the HIV-1 latent reservoir in isolated single cell subset with less sample
consumption.
Together, though further improvement and clinical verification is needed, I be-
lieve the described achievements can contribute to the improvement of latent HIV-1
reservoir characterization, and may facilitate future development of the latent HIV-
1 reservoir targeting and clearance method with the ultimate goal – to complete
cure HIV-1 infection.
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